416 related articles for article (PubMed ID: 29485002)
1. Emerging Roles of Purinergic Signaling in Diabetes.
Fotino C; Dal Ben D; Adinolfi E
Med Chem; 2018; 14(5):428-438. PubMed ID: 29485002
[TBL] [Abstract][Full Text] [Related]
2. Diabetes and hypertension: Pivotal involvement of purinergic signaling.
Reichert KP; Castro MFV; Assmann CE; Bottari NB; Miron VV; Cardoso A; Stefanello N; Morsch VMM; Schetinger MRC
Biomed Pharmacother; 2021 May; 137():111273. PubMed ID: 33524787
[TBL] [Abstract][Full Text] [Related]
3. The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis?
Kling L; Krämer BK; Yard BA; Kälsch AI
Clin Exp Rheumatol; 2018; 36 Suppl 111(2):143-151. PubMed ID: 29745882
[TBL] [Abstract][Full Text] [Related]
4. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
[TBL] [Abstract][Full Text] [Related]
5. Purinergic signaling in the pancreas and the therapeutic potential of ecto-nucleotidases in diabetes.
Cieślak M; Roszek K
Acta Biochim Pol; 2014; 61(4):655-62. PubMed ID: 25522227
[TBL] [Abstract][Full Text] [Related]
6. Divergent regulatory roles of extracellular ATP in the degranulation response of mouse bone marrow-derived mast cells.
Yoshida K; Ito M; Matsuoka I
Int Immunopharmacol; 2017 Feb; 43():99-107. PubMed ID: 27988461
[TBL] [Abstract][Full Text] [Related]
7. The role of the CD39-CD73-adenosine pathway in liver disease.
Wang S; Gao S; Zhou D; Qian X; Luan J; Lv X
J Cell Physiol; 2021 Feb; 236(2):851-862. PubMed ID: 32648591
[TBL] [Abstract][Full Text] [Related]
8. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis.
Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC
Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325
[TBL] [Abstract][Full Text] [Related]
9. Altered E-NTPDase/E-ADA activities and CD39 expression in platelets of sickle cell anemia patients.
Castilhos LG; Doleski PH; Adefegha SA; Becker LV; Ruchel JB; Leal DB
Biomed Pharmacother; 2016 Apr; 79():241-6. PubMed ID: 27044834
[TBL] [Abstract][Full Text] [Related]
10. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
11. Enzymes of the purinergic signaling system exhibit diverse effects on the degeneration of valvular interstitial cells in a 3-D microenvironment.
Weber A; Barth M; Selig JI; Raschke S; Dakaras K; Hof A; Hesse J; Schrader J; Lichtenberg A; Akhyari P
FASEB J; 2018 Aug; 32(8):4356-4369. PubMed ID: 29558203
[TBL] [Abstract][Full Text] [Related]
12. Alteration of purinergic signaling in diabetes: Focus on vascular function.
Zhou R; Dang X; Sprague RS; Mustafa SJ; Zhou Z
J Mol Cell Cardiol; 2020 Mar; 140():1-9. PubMed ID: 32057736
[TBL] [Abstract][Full Text] [Related]
13. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
[TBL] [Abstract][Full Text] [Related]
14. Enzymes involved in metabolism of extracellular nucleotides and nucleosides: functional implications and measurement of activities.
Yegutkin GG
Crit Rev Biochem Mol Biol; 2014; 49(6):473-97. PubMed ID: 25418535
[TBL] [Abstract][Full Text] [Related]
15. CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression.
Bono MR; Fernández D; Flores-Santibáñez F; Rosemblatt M; Sauma D
FEBS Lett; 2015 Nov; 589(22):3454-60. PubMed ID: 26226423
[TBL] [Abstract][Full Text] [Related]
16. Purinergic signaling: a potential therapeutic target for ischemic stroke.
Wang L; Li YJ; Yang X; Yang B; Zhang X; Zhang J; Zhang Q; Cheng XD; Wang JH; Yu NW
Purinergic Signal; 2023 Mar; 19(1):173-183. PubMed ID: 36370253
[TBL] [Abstract][Full Text] [Related]
17. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs.
Reutershan J; Vollmer I; Stark S; Wagner R; Ngamsri KC; Eltzschig HK
FASEB J; 2009 Feb; 23(2):473-82. PubMed ID: 18838482
[TBL] [Abstract][Full Text] [Related]
18. Stage-specific expression of P2Y receptors, ecto-apyrase, and ecto-5'-nucleotidase in myeloid leukocytes.
Clifford EE; Martin KA; Dalal P; Thomas R; Dubyak GR
Am J Physiol; 1997 Sep; 273(3 Pt 1):C973-87. PubMed ID: 9316419
[TBL] [Abstract][Full Text] [Related]
19. Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: how the field developed and where we are now.
Zimmermann H
Purinergic Signal; 2021 Mar; 17(1):117-125. PubMed ID: 33336318
[TBL] [Abstract][Full Text] [Related]
20. Unfolding Role of a Danger Molecule Adenosine Signaling in Modulation of Microbial Infection and Host Cell Response.
Lee JS; Yilmaz Ö
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
